SCHEMBL7019241

SCHEMBL7019241

N#Cc1ccc(-c2ccc(C=O)cc2)cc1.N#Cc1ccc(I)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 2/20 0.46
MMP3 P08254 2/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
KIF11 P52732 2/20 0.40
EGFR P00533 2/20 0.40
FBP1 P09467 4/20 0.40
MMP2 P08253 2/20 0.39
CYP11B2 P19099 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
DRD1 P21728 1/20 0.37
PTPN5 P54829 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3189884 0.90 HDAC2 (0.53) HDAC2MMP3CA12CA1CA2
SCHEMBL10382303 0.85 HDAC2 (0.57) HDAC2MMP3CA12CA1CA2
SCHEMBL7467123 0.84 MMP3 (0.58) HDAC2MMP3CA12CA1CA2
SCHEMBL7047 0.84 EGFR (0.52) HDAC2CA12CA2CA9EGFR
SCHEMBL13744792 0.84 MMP3 (0.58) HDAC2MMP3CA12CA1CA2
Water SCHEMBL29120229 0.84 EGFR (0.52) HDAC2CA12CA2CA9EGFR
SCHEMBL12037310 0.84 DRD1 (0.47) KIF11KDM4EALDH1A1DRD1
Hydrochloric Acid SCHEMBL28598774 0.82 EGFR (0.50) HDAC2CA12CA2CA9EGFR
SCHEMBL4714156 0.82 ENPP2 (0.59) HDAC2CA12CA2CA9EGFR
SCHEMBL3006203 0.78 EGFR (0.47) HDAC2CA12CA2CA9EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337517-A1 PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2003-08-27 EP disclosed
WO-2002030911-A1 PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM P.L.C. (GB) 2002-04-18 WO disclosed